NUVB Projected Dividend Yield

Com Cl A/Nuvation Bio Inc ( NYSE : NUVB )

Nuvation Bio is a clinical-stage biopharmaceutical company developing therapeutic candidates focused on treating patients with cancers. Co. is developing six wholly owned compounds that have resulted from its drug discovery and development programs, which include: NUV-422, a selective small molecule inhibitor of cyclin-dependent kinase; NUV-868, a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor; NUV-569, an oral small molecule selective inhibitor of Wee1 kinase, a regulator of DNA damage repair; and a drug-drug conjugate platform, which is a therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates.

20 YEAR PERFORMANCE RESULTS